<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
		>
<channel>
	<title>Comments on: Life sciences briefing: Tuesday, Aug. 7, 2007</title>
	<atom:link href="http://venturebeat.com/2007/08/07/life-sciences-deal-briefing-tuesday-august-7-2007/feed/" rel="self" type="application/rss+xml" />
	<link>http://venturebeat.com/2007/08/07/life-sciences-deal-briefing-tuesday-august-7-2007/</link>
	<description>News About Tech, Money and Innovation</description>
	<lastBuildDate>Wed, 25 Nov 2009 21:25:26 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.5</generator>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
		<item>
		<title>By: VentureBeat &#187; Life sciences briefing: Tuesday, Nov. 6, 2007</title>
		<link>http://venturebeat.com/2007/08/07/life-sciences-deal-briefing-tuesday-august-7-2007/comment-page-1/#comment-619502</link>
		<dc:creator>VentureBeat &#187; Life sciences briefing: Tuesday, Nov. 6, 2007</dc:creator>
		<pubDate>Wed, 07 Nov 2007 03:05:53 +0000</pubDate>
		<guid isPermaLink="false">http://venturebeat.com/2007/08/07/life-sciences-deal-briefing-tuesday-august-7-2007/#comment-619502</guid>
		<description>[...] who raise much of their funding from Asian sources. (See, for instance, our coverage of AutekBio here and of MicuRx here.) Lead Therapeutics, by contrast, raised much of its money from traditional U.S. [...]</description>
		<content:encoded><![CDATA[<p>[...] who raise much of their funding from Asian sources. (See, for instance, our coverage of AutekBio here and of MicuRx here.) Lead Therapeutics, by contrast, raised much of its money from traditional U.S. [...]</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: VentureBeat &#187; Life sciences briefing: Tuesday, Nov. 6, 2007</title>
		<link>http://venturebeat.com/2007/08/07/life-sciences-deal-briefing-tuesday-august-7-2007/comment-page-1/#comment-619516</link>
		<dc:creator>VentureBeat &#187; Life sciences briefing: Tuesday, Nov. 6, 2007</dc:creator>
		<pubDate>Wed, 07 Nov 2007 03:05:53 +0000</pubDate>
		<guid isPermaLink="false">http://venturebeat.com/2007/08/07/life-sciences-deal-briefing-tuesday-august-7-2007/#comment-619516</guid>
		<description>[...] who raise much of their funding from Asian sources. (See, for instance, our coverage of AutekBio here and of MicuRx here.) Lead Therapeutics, by contrast, raised much of its money from traditional U.S. [...]</description>
		<content:encoded><![CDATA[<p>[...] who raise much of their funding from Asian sources. (See, for instance, our coverage of AutekBio here and of MicuRx here.) Lead Therapeutics, by contrast, raised much of its money from traditional U.S. [...]</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: VentureBeat &#187; Life sciences briefing: Monday, Aug. 13, 2007</title>
		<link>http://venturebeat.com/2007/08/07/life-sciences-deal-briefing-tuesday-august-7-2007/comment-page-1/#comment-423054</link>
		<dc:creator>VentureBeat &#187; Life sciences briefing: Monday, Aug. 13, 2007</dc:creator>
		<pubDate>Mon, 13 Aug 2007 21:52:24 +0000</pubDate>
		<guid isPermaLink="false">http://venturebeat.com/2007/08/07/life-sciences-deal-briefing-tuesday-august-7-2007/#comment-423054</guid>
		<description>[...] Interestingly enough, Reliant made its last charge at the public markets with the famed Ernest Mario at the helm. Mario jumped from Reliant just last week, and is now CEO of the little-known Capnia (see our coverage here). [...]</description>
		<content:encoded><![CDATA[<p>[...] Interestingly enough, Reliant made its last charge at the public markets with the famed Ernest Mario at the helm. Mario jumped from Reliant just last week, and is now CEO of the little-known Capnia (see our coverage here). [...]</p>
]]></content:encoded>
	</item>
</channel>
</rss>
